{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:58Z","timestamp":1778166958778,"version":"3.51.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-021-04702-w","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:05:16Z","timestamp":1634918716000},"page":"1145-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darko","family":"Pucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Perincheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart E.","family":"Seropian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"4702_CR1","doi-asserted-by":"publisher","unstructured":"Shallis RM, Gale RP, Lazarus HM, et al (2021) Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2020.100773","DOI":"10.1016\/j.blre.2020.100773"},{"key":"4702_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641\u2013650","journal-title":"Biol Blood Marrow Transplant"},{"key":"4702_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1365-2141.2004.05124.x","volume":"126","author":"MA Ansari-Lari","year":"2004","unstructured":"Ansari-Lari MA, Yang CF, Tinawi-Aljundi R et al (2004) FLT3 mutations in myeloid sarcoma. Br J Haematol 126:785\u2013791","journal-title":"Br J Haematol"},{"key":"4702_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","volume":"59","author":"K Kashofer","year":"2018","unstructured":"Kashofer K, Gornicec M, Lind K et al (2018) Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma 59:501\u2013504","journal-title":"Leuk Lymphoma"},{"key":"4702_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1038\/s41375-018-0056-6","volume":"32","author":"C Willekens","year":"2018","unstructured":"Willekens C, Renneville A, Broutin S et al (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1\/2 mutations. Leukemia 32:2008\u20132081","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04702-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04702-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04702-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:05:27Z","timestamp":1649408727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04702-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4702"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04702-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual described in this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"A.M.Z. received research funding (institutional) from Celgene\/BMS, Abbvie, Astex, Pfizer, Medimmune\/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A.M.Z participated in advisory boards, and\/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene\/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, and Tyme. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. N.A.P. consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib, CTI BioPharma, PharmaEssentia, and Constellation Pharmaceuticals. N.A.P. received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, and Kartos Therapeutics. None of these relationships was related to the development of this manuscript. All other authors report no relevant disclosures\/competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}